Funding Opportunities

Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)

Application open date: November 08, 2021

Expiration Date: December 09, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.

Click here for more information about this funding opportunity!

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.

FY 2022 Concepts

• Brazil Regional Prospective Observational Research in Tuberculosis (RePORT)

Objective: The primary objective of this initiative is to enable a network of Brazilian and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant (DR)-TB, to facilitate developing tools to improve treatment outcomes at the individual level and inform strategies to curtail the TB epidemic at the public health level.

To achieve this, the initiative will support a Brazil-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within Brazil to capacitate a wide range of research.

Contact:  Dr Sudha Srinivasan

FY 2023 Concepts

• South Africa Regional Prospective Observational Research in Tuberculosis (RePORT)

Objective: The primary objective of this initiative is to enable a network of South African and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant TB, to facilitate development of tools to improve treatment outcomes at the individual level and to inform strategies to curtail the TB epidemic at the public health level.

To achieve this, the initiative will support a South Africa-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within South Africa to capacitate this research.

Contact:  Dr Sudha Srinivasan

• RePORT International Coordinating Center (RICC)

Objective: The primary objective of this initiative is to advance tuberculosis (TB) and TB/HIV research by supporting coordination of global research efforts undertaken by the various in-country Regional Prospective Observational Research for Tuberculosis (RePORT) networks and other research partners. The RePORT International Coordinating Center (RICC) enables coordination and acceleration of research across the six RePORT countries (India, Brazil, South Africa, China, Indonesia, and Philippines) and fosters a synergistic approach. This will allow for maximizing resources, validating research findings, and generating globally applicable research outcomes in a timely manner.

Contact:  Dr Sudha Srinivasan

• Biomarker Signatures of Tuberculosis Infection in Young Children With and Without HIV

Objective: The goal of this initiative is to advance research to discover and validate novel biomarkers of tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

Contact: Patrick Jean-Philippe

Click here for more information!

Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"

Contract Opportunity Type: Solicitation
 

The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five [5]-year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five [5] years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT

Post-Doctoral Research Fellowships for Global HIV and TB Public Health Programs

The mission of this fellowship program is to recruit, mentor, and train scientist-practitioners to conduct global HIV and TB research and to develop the translational and applied skills necessary to implement and support high-quality HIV and TB public health programs in global settings. The goal of this fellowship is to attract and support recent recipients of doctoral degrees to understand the underpinnings of interventional epidemiology and to prepare them for a career operating at the intersection of science and practice in global public health. The selected candidates will be in the Division of Global HIV & TB (DGHT) at the Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, GA. The DGHT Office of the Director (DGHT OD) is the lead for the program. Fellows will also be paired with DGHT’s programmatic or data branches on various projects throughout their fellowship.

The deadline to apply to this fellowship is June 30, 2021. The fellowship is scheduled to begin Fall 2021, subject to availability of funds.

Click here for more information about this fellowship!

Application Due Date: June 30, 2021. Letter of Intent Due Date: 30 days prior to the application due date.  Expires: July 01, 2021.

The purpose of this funding opportunity is to support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html?utm_campaign=+46333793&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=

First Application Due Date: June 16, 2021. Expires: May 8, 2024.

This Notice of Special Interest (NOSI) is to support projects that use data, alone or in combination, to address scientific questions and knowledge gaps in basic or clinical research in immune-mediated and infectious diseases.

Must submit to: PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-011.html

Application Due Date: Pending

The goals of this planned award are:

1) to stimulate the development and implementation of new tools and approaches to accelerate the prevention, detection and management of tuberculosis in adults and children and

2) strengthen local capacity to design, implement, disseminate and use findings from TB research.

Anticipated Award Date: 9/30/2021

https://www.usaid.gov/business-forecast/search/award/89532a8c84?search=&location=All&ouid=All&page=9

Application Due Date: June 15, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-001.html

Application Due Date(s): January 11, 2021, and December 14, 2021

This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches.

https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-018.html

Application Due Date(s): February 22, 2021, All applications are due by 5:00 PM local time of applicant organization.

To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html